FDA approves Opdivo + Yervoy to treat hepatocellular cancer (liver cancer) .- BMS
Related news and insights
AstraZeneca’s Biologics License Application (BLA) for tremelimumab (CP 675206) has been accepted for Priority Review in the US, supporting the indication of a single priming dose of the anti-CTLA4 antibody added to Imfinzi (durvalumab) for the treatment of patients with unresectable hepatocellular carcinoma (HCC).
Exelixis announced results from the final analysis of the second primary endpoint of overall survival (OS) from the phase III COSMIC-312 trial, which evaluated Cabometyx (cabozantinib) in combination with atezolizumab versus sorafenib in patients with previously untreated advanced hepatocellular carcinoma (HCC).
Merck Inc. announced the final results from the Phase III KEYNOTE-394 trial investigating Keytruda (pembrolizumab) plus best supportive care (BSC) in patients in Asia with advanced hepatocellular carcinoma (HCC) previously treated with sorafenib.